Thus, in contrast to spironolactone and eplerenone, finerenone has demonstrated to slow the progression of kidney disease and also prevent CV complications in persons with CKD and T2D on top of renin-angiotensin system inhibition [29–31]. The gene discussed is REN; the disease is chronic kidney disease.